BioSpace News Archive

Rising incidences of chronic disorders, innovations in treatment and growth in number of healthcare facilities globally is expected to drive industry growth.

Rising adoption of minimally invasive orthopedic surgery instruments and emergence of cutting-edge technologies including robotic and power-assisted technologies are expected to boost market growth.

Rising prevalence of chronic diseases such as diabetes and cancer, coupled with advancements in drug delivery methods, is expected to drive market growth.

Copenhagen, DK and Boston, MA,June 30, 2021– Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

As a Board Member of MAPS Canada and with extended training and experience in the application of Ketamine-Assisted Psychotherapy, Dr. Bhayana is at the forefront of psychedelic medicine research and advancement, directing his expertise and medical background toward the future-medicalization of psychedelic-assisted psychotherapy with an emphasis on best practices, ethics, and accessibility.

Neuroelectrics, a clinical-stage company pioneering brain stimulation therapies, has been granted FDA Breakthrough Device Designation for its Starstim® neuromodulation platform in refractory focal epilepsy.

Biocom California Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, announced that it has added Susie Harborth, executive vice president of business operations at Breakthrough Properties; Stacy Solorio, vice president of human resources at Karius; Deborah Wafer, medical scientist at Gilead and Willie Zuniga, president of Grifols Biologicals to its board of directors.

XBiotech announced it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab.

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the initiation of a new phase I study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation.

Hoag is now enrolling patients in a clinical trial to study an innovative surgical procedure that would allow surgeons to repair a patient’s mitral valve without open-heart surgery.